US EditionPublished • loading... • Updated
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
The company said the studies will highlight its first-in-class cancer therapy and TYVYT, a monoclonal antibody used in oncology.
- On Tuesday, Innovent Biologics, Inc. announced it will present clinical data for IBI363 and TYVYT at the 2026 American Society of Clinical Oncology Annual Meeting.
- Chief R&D Officer Hui Zhou stated the company is "excited to announce" the presentation, aligning with Innovent's mission to advance cancer care and address unmet medical needs globally.
- IBI363 is a first-in-class PD-1/IL-2 biased bispecific fusion protein, while TYVYT is a sintilimab injection targeting oncology, cardiovascular, metabolic, autoimmune, and ophthalmology diseases.
- The Annual Meeting runs from May 29 through early June 2026 in Chicago, providing the global platform for Innovent to share these clinical developments with the medical community.
- Innovent continues to push the boundaries of cancer care, aiming to deliver innovative and effective treatment options to physicians and patients worldwide across multiple therapeutic areas.
Insights by Ground AI
12 Articles
12 Articles
Montana Standard+11 Reposted by 11 other sources
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China, April 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…
Coverage Details
Total News Sources12
Leaning Left0Leaning Right0Center8Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
